CLASSICAL HODGKIN LYMPHOMA

This large phase 3 trial enrolled over 2900 children and teens with classical Hodgkin lymphoma. The goal was to see if doctors could reduce the use of radiation therapy without lowering cure rates. Some patients also received stronger chemotherapy to make up for less radiation. T…

This study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…

This study tested a combination of brentuximab vedotin and AVD chemotherapy in 118 adults with newly diagnosed, early-stage Hodgkin lymphoma that is considered unfavorable. The goal was to see if this treatment could cure more patients while reducing long-term side effects, espec…

This phase II trial tested a combination of the targeted drug brentuximab vedotin with standard chemotherapy (AVD) in 49 older adults with untreated Hodgkin lymphoma. The goal was to see how many patients achieved complete remission. The approach aims to improve outcomes by targe…

This study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant could help keep lymphoma from coming back. It included 82 adults with relapsed or hard-to-treat Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma. The goal was to …

This phase 2 trial tested a drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or not responded to prior treatments. Participants received the drug intravenously every two weeks. The main goal was to see how many patients' tumors shrank or disappe…

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This study tested whether giving the drug brentuximab vedotin for up to a year after a stem cell transplant could help control Hodgkin lymphoma that had returned or not responded to treatment. 14 adults took part. The goal was to see if this approach could lower the chance of the…

This study tested whether using an early PET scan after two rounds of chemotherapy can help doctors choose the right treatment for people with advanced Hodgkin lymphoma. Patients whose scan showed a good response got a milder chemo, while those with less response continued strong…

This phase 2 trial tests a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard chemotherapy in people with classical Hodgkin lymphoma that has come back or stopped responding to treatment. About 200 participants will be randomly assigned to rece…

This study tested whether a targeted drug called brentuximab vedotin (SGN-35) could replace the standard ICE chemotherapy before a stem cell transplant in 66 people with relapsed or refractory Hodgkin lymphoma. The drug targets cancer cells and has fewer side effects than ICE. Pa…

This Phase 2 trial tested the drug tislelizumab in 46 people with classical Hodgkin lymphoma that had come back or was not responding to treatment. The main goal was to see how many participants had their tumors shrink or disappear. Participants received the drug every 3 weeks un…

This study looked at 137 adults with newly diagnosed classical Hodgkin lymphoma to see if a specific genetic change (XPO1 E571K) found in their blood could signal whether cancer remains after chemotherapy. Researchers compared the blood test results with standard PET scans to mea…